FY2024 Earnings Forecast for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($3.04) per share for the year, down from their prior estimate of ($2.65). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.73) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.55) EPS and FY2027 earnings at ($2.51) EPS.

LXEO has been the subject of a number of other research reports. Chardan Capital increased their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, HC Wainwright increased their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $22.71.

Lexeo Therapeutics Stock Down 9.8 %

Shares of LXEO stock opened at $6.00 on Monday. Lexeo Therapeutics has a one year low of $5.81 and a one year high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. The stock has a fifty day moving average price of $9.01 and a 200 day moving average price of $12.23. The stock has a market cap of $198.40 million and a P/E ratio of -1.93.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 12,500 shares of company stock valued at $113,300 in the last three months. 4.50% of the stock is owned by corporate insiders.

Institutional Trading of Lexeo Therapeutics

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. acquired a new position in Lexeo Therapeutics in the third quarter valued at about $67,000. American International Group Inc. bought a new position in Lexeo Therapeutics during the first quarter worth about $79,000. MetLife Investment Management LLC grew its position in shares of Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after buying an additional 7,803 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after acquiring an additional 3,627 shares during the last quarter. 60.67% of the stock is owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.